Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Return on Sales (2016 - 2025)

BioCorRx (BICX) has disclosed Return on Sales for 15 consecutive years, with 1.25% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 67873.0% to 1.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.04% through Dec 2025, up 67795.0% year-over-year, with the annual reading at 4.4% for FY2025, 67559.0% up from the prior year.
  • Return on Sales hit 1.25% in Q4 2025 for BioCorRx, down from 0.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.0% in Q3 2025 to a low of 679.99% in Q4 2024.
  • Historically, Return on Sales has averaged 117.82% across 5 years, with a median of 59.34% in 2021.
  • Biggest five-year swings in Return on Sales: plummeted -62882bps in 2024 and later skyrocketed 67873bps in 2025.
  • Year by year, Return on Sales stood at 88.39% in 2021, then skyrocketed by 84bps to 13.94% in 2022, then crashed by -267bps to 51.17% in 2023, then plummeted by -1229bps to 679.99% in 2024, then skyrocketed by 100bps to 1.25% in 2025.
  • Business Quant data shows Return on Sales for BICX at 1.25% in Q4 2025, 0.0% in Q3 2025, and 7.73% in Q2 2025.